206 results
8-K
EX-99.1
LSTA
Lisata Therapeutics Inc
9 May 24
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:08pm
for the BOLSTER trial, partially offset by a reduction in expenses associated with the Phase 2b ASCEND trial which completed enrollment in the prior … fees partially offset by one-off settlement-related costs.
Overall, net losses were $5.4 million for the three months ended March 31, 2024, compared
8-K
EX-99.1
LSTA
Lisata Therapeutics Inc
29 Feb 24
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
4:09pm
offset by severance costs associated with the elimination of the Chief Business Officer position on May 1, 2023.
Overall, net losses were $20.8 million
8-K
EX-99.1
15szt1bdl ln47644
14 Aug 23
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.1
4lka 36yx
9 May 23
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.1
2ei0 b6jh2
30 Mar 23
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
4:07pm
8-K
EX-99.1
a42sw3w 1g
10 Nov 22
Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
4:10pm
8-K/A
EX-99.3
ktrq0ocm
4 Oct 22
Other Events
4:42pm
8-K/A
EX-99.2
27siqrv91pj4phd3 zr
4 Oct 22
Other Events
4:42pm
424B3
qyjvkdd4xdhio
29 Jul 22
Prospectus supplement
4:06pm